Articles: 30.04 April 2019

Hypertension – who to treat?

In this editorial, Rupert Payne, Consultant Editor on Prescriber, discusses the revision to the management of hypertension, to be published in the NICE guidance in August 2019, to lower the threshold for drug treatment for those patients with milder forms of high blood pressure

More details...

Progress in the long battle against antimicrobial resistance

The annual ESPAUR report provides a roundup of the achievements of the UK Five Year Antimicrobial Resistance Strategy 2013 to 2018 in terms of antimicrobial consumption, resistance, and stewardship in England. This article summarises the findings of the 2018 report

More details...

Diagnosis and management of hypertension in primary care

Hypertension is a major modifiable risk factor for cardiovascular disease, but conflicting opinions remain about optimal blood pressure targets. This article discusses the various definitions of hypertension, provides guidance on management in primary care and advises when referral to secondary care is needed

More details...

How social prescribing can benefit patients and prescribers

Social prescribing has the potential to address unmet patient needs and ease pressure on GPs and other healthcare professionals. This article investigates the evidence behind social prescribing, the benefits and drawbacks, and how it is gaining a higher profile in the

More details...

Opioid use in palliative care: new developments and guidelines

The correct use of opioids is the mainstay of effective management of pain in palliative care. This article describes the available analgesic options, reviews recent evidence and guidelines, and explores patients’ and doctors’ common concerns about opioid use

More details...

Managing severe asthma: back to the basic elements of care

Severe asthma is potentially life threatening. Newer biological therapies may offer a beacon of hope for some patients. However, it is important to address the basics first, such as comorbidities that can contribute to poorly controlled asthma, and clear diagnostic guidelines and criteria for referral are still needed

More details...

Monitoring the growing use of esomeprazole

Like all proton-pump inhibitors (PPIs), esomeprazole has a generally good safety record. However, there is no true low potency formulation of esomeprazole available and therefore the growing use of this drug may increase the risk of dose dependent PPI adverse effects, argues Angus Thompson

More details...

Web design and marketing agency Leamington Spa